ARVINAS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ARVINAS, INC. (ARVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-04
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $0.00.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $0.00.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $0.00.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $3.60M, a 157.14% increase from fiscal 2023.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.40M, a 82.28% decline from fiscal 2022.
- ARVINAS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $7.90M, a 83.16% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $100.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $100.00K derived: sum of 3 quarters · filed 2026-05-11 | $2.70M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $100.00K derived: sum of 2 quarters · filed 2026-02-24 | $2.70M derived: sum of 3 quarters · filed 2026-02-24 | $3.60M 10-K · filed 2026-02-24 |
| 2024-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.70M derived: sum of 2 quarters · filed 2025-11-05 | $3.60M 10-Q · filed 2025-11-05 | $4.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.50M 10-Q · filed 2025-08-06 | $4.00M derived: sum of 3 quarters · filed 2026-02-24 | $4.30M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $900.00K 10-Q · filed 2025-05-01 | $1.40M derived: sum of 2 quarters · filed 2026-02-24 | $1.70M derived: sum of 3 quarters · filed 2026-02-24 | $1.80M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $800.00K derived: sum of 2 quarters · filed 2026-02-24 | $900.00K derived: sum of 3 quarters · filed 2026-02-24 | $1.40M 10-K · filed 2026-02-24 |
| 2023-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $400.00K derived: sum of 2 quarters · filed 2024-10-30 | $900.00K 10-Q · filed 2024-10-30 | $1.20M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $600.00K 10-Q · filed 2024-07-30 | $900.00K derived: sum of 3 quarters · filed 2025-02-11 | $1.40M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $500.00K 10-Q · filed 2024-05-07 | $800.00K derived: sum of 2 quarters · filed 2025-02-11 | $1.30M derived: sum of 3 quarters · filed 2025-02-11 | $2.50M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $800.00K derived: sum of 2 quarters · filed 2025-02-11 | $2.00M derived: sum of 3 quarters · filed 2025-02-11 | $7.90M 10-K · filed 2025-02-11 |
| 2022-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.70M derived: sum of 2 quarters · filed 2023-11-07 | $7.60M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $7.10M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $5.90M 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $46.90M 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $19.40M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $1.90M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |